Opinions mine. She/Her.
Learn more: brnw.ch/21wSP18
Learn more: brnw.ch/21wSP18
Read full article: brnw.ch/21wSn7M
Read full article: brnw.ch/21wSn7M
Submit feedback to us by May 15: brnw.ch/21wSljI
Submit feedback to us by May 15: brnw.ch/21wSljI
ascopubs.org/doi/full/10....
ascopubs.org/doi/full/10....
Read more. brnw.ch/21wS8TZ
Read more. brnw.ch/21wS8TZ
➡️ fertility preservation options for men/women/children
➡️ established and emerging methods discussed
➡️ fertility preservation options for men/women/children
➡️ established and emerging methods discussed
Tell us about:
🔵 the issue
🔵 how the policy aligns with ASCO’s goals
🔵 suggestions for potential policy writers
Tell us about:
🔵 the issue
🔵 how the policy aligns with ASCO’s goals
🔵 suggestions for potential policy writers
Topics include established, emerging, & investigational fertility preservation methods for adults & children and importance of discussing infertility risks with all patients
ascopubs.org/doi/10.1200/...
Topics include established, emerging, & investigational fertility preservation methods for adults & children and importance of discussing infertility risks with all patients
ascopubs.org/doi/10.1200/...
and post-conversion assessments link.springer.com/article/10.1... @ascocancer.bsky.social @cancercaremascc.bsky.social @aahpm.bsky.social
and post-conversion assessments link.springer.com/article/10.1... @ascocancer.bsky.social @cancercaremascc.bsky.social @aahpm.bsky.social
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
▶️ Discussion of 2nd line options
▶️ Update on T-Dxd for HER2 IHC3+ lungcancer
▶️ No consensus on use of TTF, Dato-DXd
👉🏽 ascopubs.org/doi/10.1200/...
▶️ Discussion of 2nd line options
▶️ Update on T-Dxd for HER2 IHC3+ lungcancer
▶️ No consensus on use of TTF, Dato-DXd
👉🏽 ascopubs.org/doi/10.1200/...
Read more: brnw.ch/21wR0fb
Read more: brnw.ch/21wR0fb
#LungCancer #LCSM
#LungCancer #LCSM
Updated recommendations for stage IV NSCLC without driver alterations include a new second-line option for patients with good PS & HER2 overexpression #ASCOguidelines
ascopubs.org/doi/10.1200/...
Updated recommendations for stage IV NSCLC without driver alterations include a new second-line option for patients with good PS & HER2 overexpression #ASCOguidelines
ascopubs.org/doi/10.1200/...